mardi 15 mai 2018

Onco Actu du 15 mai 2018

1. Biologie

Pancreatic cancer foiled by a switch of tumour subtype [Nature]

1.4 Biologie - Technos

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M [Xconomy]

Feng Zhang, David Liu's base-editing CRISPR startup officially launches with $87M [FierceBiotech]

2.5 Etiologie - Gènes

Are common diseases generally caused by 'common' variants? [Mermaid's Tale]

4.1 Dép., diag. & prono. - Prostate

A win for readers: coverage of new prostate cancer screening guidelines focuses on shared decision making [HealthNewsReview]

4.2 Dép., diag. & prono. - Génome

Breast cancer patients increasingly receive multigene testing [Stanford Medicine]

The Ancestral Pace of Variant Reclassification [JNCI]

4.5 Dép., diag. & prono. - Colorectal

Immunoscore for colon cancer [BMJ Blogs]

4.9 Dép., diag. & prono. - Sein

Women could 'pay the price' of botched attempts to tackle screening scandal [The Telegraph]

Margaret McCartney: Can we now talk openly about the risks of screening? [BMJ]

5.12.7 Immunothérapies - vaccins

PET scan tracer could predict efficacy of cancer “vaccine” [Stanford Medicine]

5.2 Pharma

TP brings on Adverum’s ex-CMO following launch of first-in-human study [FierceBiotech]

Cambridge spinout CellCentric gets $26M for single-asset epigenetics approach to prostate cancer [EndPoints]

Targeting the tricky P13K pathway in cancer, MEI gets $75M to push program through registration study [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa [Xconomy]

Lilly to buy cancer drug developer AurKa Pharma [Reuters]

Eli Lilly’s oncology R&D spree continues with $576M deal to buy a startup and reel back Aurora A drug [EndPoints]

5.2.3 Pharma - économie

ATyr slashes headcount, cuts costs after ORCA runs aground [FierceBiotech]

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising [STAT]

5.3.4 Traitements - AMM (FDA, EMA,...)

EMA Recommends a New Formulation and Extension of Indications for Dasatinib [ESMO]

5.9 AACR

Last Month in Oncology with Dr. Bishal Gyawali: April 2018 [ecancernews]

6. Lutte contre les cancers

Head of Biden Cancer Initiative draws on own diagnosis to speed research [STAT]

Health Affairs New Issue: Precision Medicine [Health Affairs]

Brain cancer to get more funding in tribute to Tessa Jowell, says No 10 [The Guardian]

6.10.1 Politiques (USA)

Azar, striking an aggressive tone, suggests Trump will call out drug companies behind major price hikes [STAT]

Trump Administration's 3 Biggest Ideas For Lowering Drug Prices [NPR]

HHS Secretary Azar talks about more brass knuckle tactics on drug prices, but investors shrug it off again [EndPoints]

What Trump Should Actually Do About the High Cost of Drugs [NY Times]

Just Saying Yes to Drug Companies [NY Times]

6.11 Patients

Cancer patients urged to discuss 'end of life' plans [BBC News]

Pressure to stay positive may be a negative for cancer patients [The Guardian]

6.7 DMP, Big Data & applis

Techonomy NYC: With Precision Medicine, Every Disease will be a ‘Rare Disease’ [Techonomy]

How big data can help prostate cancer patients [ecancernews]

6.7.2 Applis

Apple Health Records: Where early adopters see the biggest impact so far [Healthcare IT News]

6.9 Controverses

As Twitter explodes, Eric Lander apologizes for toasting James Watson [STAT]

A cancer researcher said she collected blood from 98 people. It was all her own. [Retraction Watch]

Blood, sweat and tears in biotech — the Theranos story [Nature]

J&J defends itself in trial over baby powder asbestos claims [Reuters]